Your browser doesn't support javascript.
loading
Topiramate for pediatric migraine prevention.
Can Fam Physician ; 63(7): 529-531, 2017 Jul.
Article en En | MEDLINE | ID: mdl-28701441
Question I have several teenagers in my clinic with migraine headache and some of them have frequent episodes that cause considerable interference with daily activity. I would like to offer them prophylactic therapy to reduce the frequency of their migraine episodes. Is topiramate an effective and safe option for adolescents? Answer Both Health Canada and the US Food and Drug Administration have approved the use of topiramate for migraine prevention in adults; however, only the US Food and Drug Administration has approved topiramate for migraine prophylaxis in adolescents 12 to 17 years of age. Although several studies support its effectiveness in preventing migraine, most of these studies are small; and a recent large multicentre, randomized placebo-controlled trial was stopped early when no benefit was shown over placebo. Adverse effects of topiramate are mild and typically resolve over time. The recommended dosage is 2 mg/kg per day, up to an adult dose of 100 mg/d.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Neuroprotectores / Fructosa / Trastornos Migrañosos Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Child / Humans País/Región como asunto: America do norte Idioma: En Revista: Can Fam Physician Año: 2017 Tipo del documento: Article Pais de publicación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Neuroprotectores / Fructosa / Trastornos Migrañosos Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Child / Humans País/Región como asunto: America do norte Idioma: En Revista: Can Fam Physician Año: 2017 Tipo del documento: Article Pais de publicación: Canadá